{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:48:08Z","timestamp":1785610088628,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2015.13"],"award-info":[{"award-number":["DKS 2015.13"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["2009.09"],"award-info":[{"award-number":["2009.09"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2012.06"],"award-info":[{"award-number":["DKS 2012.06"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2018.10"],"award-info":[{"award-number":["DKS 2018.10"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2021.04"],"award-info":[{"award-number":["DKS 2021.04"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020046","name":"DKMS Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.eclinm.2024.102957","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T16:18:51Z","timestamp":1732897131000},"page":"102957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-7569","authenticated-orcid":false,"given":"Ewa","family":"Koscielniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernarda","family":"Kazanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Niggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sparber-Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hallmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Teichert von L\u00fcttichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Behnisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ladenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Scheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vokuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thekla","family":"von Kalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Blattmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bielack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eclinm.2024.102957_bib1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.1995.13.8.2123","article-title":"Biology and therapy of pediatric rhabdomyosarcoma","volume":"13","author":"Pappo","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102957_bib2","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1200\/JCO.2005.08.130","article-title":"Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric oncology--SIOP malignant mesenchymal tumor 89","volume":"23","author":"Stevens","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102957_bib3","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.1999.17.12.3706","article-title":"Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86","volume":"17","author":"Koscielniak","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.eclinm.2024.102957_bib4","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2011.40.3287","volume":"30","author":"Oberlin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102957_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29691","article-title":"Long-term results from the multicentric European randomized phase 3 trial CWS\/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults","volume":"69","author":"Sparber-Sauer","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102957_bib6","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.eclinm.2024.102957_bib7","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2009.22.3768","article-title":"Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803","volume":"27","author":"Arndt","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102957_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ctrv.2018.06.013","article-title":"Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned","volume":"68","author":"Arndt","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102957_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/pbc.21494","article-title":"Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial","volume":"50","author":"Klingebiel","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102957_bib10","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102957_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102957_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0197-2456(81)90001-5","article-title":"Introduction to sample size determination and power analysis for clinical trials","volume":"2","author":"Lachin","year":"1981","journal-title":"Control Clin Trials"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102957_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pbc.21906","article-title":"Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas?","volume":"52","author":"Mattke","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102957_bib14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.eclinm.2024.102957_bib15","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1200\/JCO.22.02673","article-title":"Which patients with rhabdomyosarcoma need radiotherapy? Analysis of the radiotherapy strategies of the CWS-96 and CWS-2002P studies and SoTiSaR registry","volume":"41","author":"Koscielniak","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102957_bib16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(18)30337-1","article-title":"Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial","volume":"19","author":"Bisogno","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102957_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29145","article-title":"Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS)","volume":"68","author":"Koscielniak","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102957_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001813-199706000-00002","article-title":"Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer","volume":"8","author":"Wagner","year":"1997","journal-title":"Anticancer Drugs"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102957_bib19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5414\/CPP42652","article-title":"Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis","volume":"42","author":"Stolting","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102957_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00685858","article-title":"Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma","volume":"36","author":"Blomqvist","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eclinm.2024.102957_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2019.10.016","article-title":"Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma","volume":"124","author":"Hartmann","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102957_bib22","first-page":"39","article-title":"Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience","volume":"23","author":"Raciborska","year":"2019","journal-title":"Dev Period Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102957_bib23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1200\/JCO.2007.15.0466","article-title":"Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults","volume":"27","author":"Dantonello","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102957_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00043426-200105000-00010","article-title":"Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group","volume":"23","author":"Breitfeld","year":"2001","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102957_bib25","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2005.01.9497","article-title":"Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group","volume":"24","author":"Soft Tissue Sarcoma Committee of the Children's Oncology Group","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102957_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28174","article-title":"An unresolved issue in rhabdomyosarcoma treatment: the duration of chemotherapy","volume":"67","author":"Bisogno","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102957_bib27","article-title":"Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102957_bib28","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.22.00409","article-title":"Circulating tumor DNA is prognostic in intermediate-risk rhabdomyosarcoma: a report from the children's oncology group","volume":"41","author":"Abbou","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102957_bib29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1470-2045(24)00255-9","article-title":"Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group","volume":"25","author":"Gupta","year":"2024","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102957_bib30","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.ejca.2008.07.026","article-title":"Clinical trials for children with cancer in Europe - still a long way from harmonisation: a report from SIOP Europe","volume":"44","author":"Pritchard-Jones","year":"2008","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.eclinm.2024.102957_bib31","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in ewing sarcoma with pulmonary metastases: results of the European ewing tumour working initiative of national groups, 99 trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:34:52Z","timestamp":1764624892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024005364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"alternative-id":["S2589537024005364"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102957","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102957"}}